771 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
REGN Regeneron Pharmaceuticals, Inc. $386.665 $41.78B Downtrend
Article Searches
Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs http://www.zacks.com/stock/news/326050/biotech-stock-roundup-alxn-on-acquisition-spree-fda-nod-for-regn-amgn-drugs?cid=CS-ZC-FT-326050 Oct 03, 2018 - The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.
Cancer Investing Highlight: Another One Joins The Big Immunotherapy Contest https://seekingalpha.com/article/4209286-cancer-investing-highlight-another-one-joins-big-immunotherapy-contest?source=feed_sector_healthcare Oct 02, 2018 - Regeneron is part of a pack of new checkpoint inhibitor developers in solid tumor oncology.Their entry to the PD-1 space recently was approved for a new indication in the field.What does it mean for t
Sanofi/Regeneron's Cemiplimab Wins FDA Nod for Skin Cancer http://www.zacks.com/stock/news/325705/sanofi-regenerons-cemiplimab-wins-fda-nod-for-skin-cancer?cid=CS-ZC-FT-325705 Oct 01, 2018 - Sanofi (SNY)/Regeneron's (REGN) anti- PD-1 drug cemiplimab wins FDA approval for a type of skin cancer.
With life-threatening food allergies on the rise, drug companies ramp up new approaches https://www.cnbc.com/2018/09/27/with-food-allergies-on-the-rise-drug-companies-ramp-up-new-approaches.html Sep 27, 2018 - Allergies are on the rise and researchers are trying new methods to help combat potentially life threatening reactions.
FDA Lifts Clinical Hold on Sarepta's DMD Gene Therapy Program http://www.zacks.com/stock/news/324777/fda-lifts-clinical-hold-on-sareptas-dmd-gene-therapy-program?cid=CS-ZC-FT-324777 Sep 25, 2018 - The FDA has lifted clinical hold on Sarepta's (SRPT) clinical study evaluating the Duchenne muscular dystrophy micro-dystrophin gene therapy program. The clinical hold was placed in July by the FDA.
CHMP Reconfirms Negative Opinion for Sarepta's Exondys http://www.zacks.com/stock/news/324582/chmp-reconfirms-negative-opinion-for-sareptas-exondys?cid=CS-ZC-FT-324582 Sep 24, 2018 - The CHMP re-confirmed the negative opinion for Sarepta's (SRPT) Exondys, which is developed to treat individuals who have a specific type of Duchenne muscular dystrophy.
Novartis Gets Positive CHMP Opinion for Drugs, Biosimilar http://www.zacks.com/stock/news/324579/novartis-gets-positive-chmp-opinion-for-drugs-biosimilar?cid=CS-ZC-FT-324579 Sep 24, 2018 - Novartis (NVS) gets positive CHMP opinion for a label expansion of Gilenya, gene therapy, and a biosimilar of Neulasta.
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences http://www.zacks.com/stock/news/323964/the-zacks-analyst-blog-highlights-regeneron-pharmaceuticals-celgene-sanofi-and-gilead-sciences?cid=CS-ZC-FT-323964 Sep 20, 2018 - The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences
Eylea Competition Coming But Pipeline Could Maintain Growth For Regeneron https://seekingalpha.com/article/4207219-eylea-competition-coming-pipeline-maintain-growth-regeneron?source=feed_sector_healthcare Sep 19, 2018 - Eylea represents a significant portion of revenue and will face upcoming competition, which could slow Regeneron sales growth over the coming years.Eylea recently received approval for a 12 week dose,
GameStop's Fundamentals Are Declining - Cramer's Lightning Round (9/18/18) https://seekingalpha.com/article/4207068-gamestops-fundamentals-declining-cramers-lightning-round-9-18-18?source=feed_tag_cramers_picks Sep 19, 2018 - Regeneron and Amgen are better picks than Biogen.The refiners are doing well.Book profits on Liberty Oilfield Services.

Pages: 123456...78

Page 1>

Related Companies

Name Exchange Price Mkt Cap
ZTS Zoetis Inc. NYSE $88.3 $42.55B
VRTX Vertex Pharmaceuticals Incorporated NASDAQ $175.8 $44.93B
SHPG Shire plc NASDAQ $176.25 $46.08B
ALXN Alexion Pharmaceuticals, Inc. NASDAQ $117.77 $26.25B
TEVA Teva Pharmaceutical Industries Limited NYSE $23.43 $23.86B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Regeneron Pharmaceuticals